• Our Science
  • Clinical Expertise
  • Our Company
  • Investors
  • News & Media
  • Contact
  • News Room
    
    Our Company
    • Preview
    • Home V1
    • Home V2
    • Home V3
    • About
    • Services
    • Service single
    • Papers
    • Paper single
    • Careers
    • Career single
    • Blog V1
    • Blog V2
    • Blog V3
    • Blog post
    • Contact V1
    • Contact V2
    • Contact V3
    • Pricing
    • Pricing single
    • Coming soon
    • More Webflow Template
    Utility pages
    • Start here
    • Style guide
    • 404 not found
    • Password protected
    • Licenses
    • Changelog

In the News

5Q Spectra media coverage, official announcements, and recognition from the diagnostics and healthcare industry in one place for journalists, investors, and partners.

News

Major U.S. Patient Studies Unveiled by 5Q Spectra at Davos Healthcare™

September 14, 2026

Articles

Beyond Cancer Biopsy: How 5Q Spectra is Advancing Early Cancer Detection, Care & Treatment

September 14, 2026

Articles

A Breakthrough Blood Test for Prostate Cancer To be Premiered by 5Q Spectra at Davos of Healthcare™

September 8, 2026

Articles

At the Davos of Healthcare Summit, announced a Breakthrough in 5Q Spectra’s Prostate Dx™ to Advance Blood-Based Cancer Diagnostics

September 10, 2026


Latest posts

AllNews
AllArticles
AllResources
Major U.S. Patient Studies Unveiled by 5Q Spectra at Davos Healthcare™
News
Sep 15, 2026

Major U.S. Patient Studies Unveiled by 5Q Spectra at Davos Healthcare™

Beyond Cancer Biopsy: How 5Q Spectra is Advancing Early Cancer Detection, Care & Treatment
Articles
Sep 15, 2026

Beyond Cancer Biopsy: How 5Q Spectra is Advancing Early Cancer Detection, Care & Treatment

A Breakthrough Blood Test for Prostate Cancer To be Premiered by 5Q Spectra at Davos of Healthcare™
Articles
Sep 15, 2026

A Breakthrough Blood Test for Prostate Cancer To be Premiered by 5Q Spectra at Davos of Healthcare™

At the Davos of Healthcare Summit, announced a Breakthrough in 5Q Spectra’s Prostate Dx™ to Advance Blood-Based Cancer Diagnostics
Articles
Sep 15, 2026

At the Davos of Healthcare Summit, announced a Breakthrough in 5Q Spectra’s Prostate Dx™ to Advance Blood-Based Cancer Diagnostics

HomeOur ScienceClinical ExpertiseOur CompanyInvestorsContact

Contact Us

info@5qspectra.com1-250-558-9639

ProstateDx™ is a laboratory developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Testing is performed as a laboratory developed test (LDT) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to conduct high-complexity testing.
‍

Copyright © 2026 5Q Spectra